Form 4: BiomX Inc. Insider Transactions: Deerfield Funds Exercise Warrants and Acquire Common Stock

Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. exercised warrants to acquire BiomX Inc. common stock at a reduced price, while also receiving new warrants and amending existing ones.

Summary

• On February 27, 2025, Deerfield Private Design Fund V, L.P. (DPD V) and Deerfield Healthcare Innovations Fund II, L.P. (HIF II) exercised their Private Placement Warrants for cash, acquiring 1,611,864 shares of BiomX Inc. common stock each.
• The exercise price was reduced to $0.9306 per share under an Inducement Letter Agreement.
• Due to beneficial ownership limitations, each fund received 353,249 shares of common stock and an amended warrant for the remaining 1,258,614 shares.
• The amended warrants have a reduced exercise price of $0.0001 per share (in addition to the pre-funded $0.9305) and an extended expiration date.
• New warrants to purchase up to 1,611,864 shares of common stock were issued to each fund, with an exercise price of $0.9306 per share, but these are not currently exercisable pending stockholder approval.
• James E. Flynn, along with several Deerfield entities, jointly filed the Form 4.
• Jonathan Isler, Attorney-in-Fact, signed the document on behalf of the reporting persons.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the warrant exercise provides capital, the potential dilution and need for stockholder approval introduce uncertainty.

Positives

• The exercise of warrants provides BiomX Inc. with additional capital.
• The reduced exercise price may incentivize further investment from Deerfield.
• The extension of the warrant expiration date provides Deerfield with long-term investment potential.

Negatives

• The reduced exercise price for the warrants could dilute existing shareholders' equity.
• The issuance of new warrants could further dilute shareholders if exercised in the future.
• Stockholder approval is required for the new warrants to become exercisable, creating uncertainty.

Risks

• The new warrants are not currently exercisable and require stockholder approval.
• The exercise of warrants and issuance of new warrants could lead to dilution of existing shareholders.
• The beneficial ownership limitations could restrict future acquisitions of common stock by the funds.

Future Outlook

The new warrants are not currently exercisable and will not become exercisable unless and until requisite stockholder approval is obtained.

Industry Context

This announcement reflects ongoing investment activity in the biotechnology sector, where warrant exercises and equity adjustments are common financing mechanisms.

Comparison to Industry Standards

• Warrant exercises and amendments are common in the biotech industry, particularly for companies like BiomX seeking funding for research and development.
• Similar transactions can be seen with companies like CRISPR Therapeutics and Editas Medicine, where strategic investors adjust their holdings through warrant agreements.
• The reduced exercise price and extended expiration dates are typical incentives offered to major investors to maintain their commitment to the company's long-term success.

Stakeholder Impact

• Existing shareholders may experience dilution if the new warrants are exercised.
• The company benefits from the additional capital provided by the warrant exercise.
• Deerfield benefits from the reduced exercise price and extended expiration date of the warrants.

Next Steps

• Obtain stockholder approval for the new warrants to become exercisable.
• Monitor the exercise of the amended warrants.
• Observe any further transactions by Deerfield related to BiomX Inc. securities.

Key Dates